v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 29, 2026
Dec. 31, 2025
Assets    
Cash and cash equivalents $ 1,703 $ 1,142
Short-term investments 11,372 12,454
Trade accounts receivable, net of allowance for doubtful accounts: 2026—$425; 2025—$427 12,585 11,874
Inventories 10,667 10,654
Current tax assets 3,588 3,967
Other current assets 2,908 2,808
Total current assets 42,822 42,898
Long-term investments 1,626 1,621
Property, plant and equipment, net of accumulated depreciation: 2026—$17,803; 2025—$17,386 19,402 19,317
Identifiable intangible assets, net 52,559 53,731
Goodwill 71,409 71,264
Noncurrent deferred tax assets and other noncurrent tax assets 9,965 9,699
Other noncurrent assets 9,834 9,631
Total assets 207,618 208,160
Liabilities and Equity    
Short-term borrowings, including current portion of long-term debt: 2026—$3,861; 2025—$2,997 3,890 3,154
Trade accounts payable 4,506 5,240
Dividends payable 0 2,445
Income taxes payable 3,130 3,103
Accrued compensation and related items 2,715 3,610
Other current liabilities 20,108 19,432
Total current liabilities 34,348 36,984
Long-term debt 60,565 61,641
Pension and postretirement benefit obligations 1,984 2,041
Noncurrent deferred tax liabilities 2,412 2,401
Other taxes payable 3,705 3,591
Other noncurrent liabilities 14,200 14,725
Total liabilities 117,214 121,385
Commitments and Contingencies
Common stock 482 481
Additional paid-in capital 94,773 94,469
Treasury stock (115,190) (115,015)
Retained earnings 117,238 114,610
Accumulated other comprehensive loss (7,203) (8,069)
Total Pfizer Inc. shareholders’ equity 90,101 86,476
Equity attributable to noncontrolling interests 303 299
Total equity 90,404 86,775
Total liabilities and equity $ 207,618 $ 208,160